NCT05761470View on ClinicalTrials.gov

Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

May 6, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2028

Conditions
Her-2 Negative Breast CancerHRR Gene Mutation
Interventions
DRUG

Camrelizumab

"Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle.~Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle."

DRUG

Fluzoparib

Fluzoparib

DRUG

Nab-paclitaxel

Nab-paclitaxel

Trial Locations (1)

510080

RECRUITING

First Affiliated Hospital, Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Ying Lin

OTHER